tiprankstipranks
Trending News
More News >
HYUGA PRIMARY CARE Co.,Ltd. (JP:7133)
:7133
Japanese Market
Advertisement

HYUGA PRIMARY CARE Co.,Ltd. (7133) AI Stock Analysis

Compare
0 Followers

Top Page

JP:7133

HYUGA PRIMARY CARE Co.,Ltd.

(7133)

Rating:71Outperform
Price Target:
¥1,484.00
▲(12.59% Upside)
The overall stock score of 71 reflects HYUGA PRIMARY CARE Co.,Ltd.'s strong financial performance and reasonable valuation. While technical indicators suggest a bearish trend, the stock's nearing oversold conditions could offer a buying opportunity. The absence of recent earnings call insights and corporate events limits additional context.

HYUGA PRIMARY CARE Co.,Ltd. (7133) vs. iShares MSCI Japan ETF (EWJ)

HYUGA PRIMARY CARE Co.,Ltd. Business Overview & Revenue Model

Company DescriptionHYUGA PRIMARY CARE Co.,Ltd. (7133) specializes in providing primary healthcare services in Japan. The company focuses on delivering accessible and comprehensive medical care, aiming to improve the overall health and well-being of its patients. Its services range from routine check-ups and preventive care to chronic disease management, aiming to cater to a wide range of health needs within the community.
How the Company Makes MoneyHYUGA PRIMARY CARE Co.,Ltd. generates revenue primarily through its healthcare services, which include patient consultations, diagnostic tests, and treatments. The company earns money by charging fees for these medical services, which may be paid directly by the patients or covered by insurance providers. Additionally, the company may have partnerships with local healthcare facilities or insurance companies to expand its reach and enhance service delivery. These collaborations can play a crucial role in driving patient volume and ensuring steady revenue streams.

HYUGA PRIMARY CARE Co.,Ltd. Financial Statement Overview

Summary
HYUGA PRIMARY CARE Co.,Ltd. exhibits strong financial performance with significant revenue growth, healthy profit margins, and solid cash flow management. The balance sheet shows disciplined leverage and equity management, although rising liabilities need careful monitoring.
Income Statement
85
Very Positive
HYUGA PRIMARY CARE Co.,Ltd. has demonstrated strong revenue growth over recent years, with a notable increase from 4,331 million JPY in 2020 to 9,984 million JPY in 2025. The company has maintained healthy gross profit and net profit margins, indicating efficient cost management and profitability. The EBIT and EBITDA margins further highlight operational efficiency, contributing to a strong financial position.
Balance Sheet
78
Positive
The company's balance sheet reflects a solid equity base, with stockholders' equity increasing significantly over the years. The debt-to-equity ratio has been managed well, showing a stable leverage position. Return on equity has improved, indicating effective use of shareholder funds. However, the total liabilities have also increased, necessitating careful financial management to maintain stability.
Cash Flow
82
Very Positive
HYUGA PRIMARY CARE Co.,Ltd. has shown consistent growth in free cash flow, supported by strong operating cash flows. The operating cash flow to net income ratio is robust, indicating good cash generation relative to earnings. Despite fluctuations in capital expenditures, the company has managed to maintain positive free cash flow, supporting its operational and expansion activities.
BreakdownMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue9.98B8.29B6.66B5.78B5.09B
Gross Profit2.41B1.88B1.56B1.24B783.83M
EBITDA1.31B854.38M627.27M568.69M258.55M
Net Income719.03M441.03M382.88M328.45M97.14M
Balance Sheet
Total Assets7.05B6.35B2.91B2.53B2.02B
Cash, Cash Equivalents and Short-Term Investments565.93M688.01M567.69M719.56M538.29M
Total Debt2.65B2.80B251.54M330.21M447.63M
Total Liabilities4.68B4.71B1.43B1.46B1.41B
Stockholders Equity2.37B1.64B1.48B1.07B609.46M
Cash Flow
Free Cash Flow485.51M473.20M102.59M228.92M277.22M
Operating Cash Flow771.32M706.64M342.25M484.60M351.82M
Investing Cash Flow-473.98M-1.13B-383.39M-320.25M-77.59M
Financing Cash Flow-419.43M538.78M-110.73M16.93M36.64M

HYUGA PRIMARY CARE Co.,Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1318.00
Price Trends
50DMA
1445.74
Negative
100DMA
1403.72
Negative
200DMA
1324.76
Negative
Market Momentum
MACD
-9.52
Positive
RSI
33.76
Neutral
STOCH
8.32
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7133, the sentiment is Negative. The current price of 1318 is below the 20-day moving average (MA) of 1475.30, below the 50-day MA of 1445.74, and below the 200-day MA of 1324.76, indicating a bearish trend. The MACD of -9.52 indicates Positive momentum. The RSI at 33.76 is Neutral, neither overbought nor oversold. The STOCH value of 8.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7133.

HYUGA PRIMARY CARE Co.,Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
¥20.05B11.45
3.81%4.31%-9.01%
75
Outperform
¥3.20B10.98
2.63%4.76%134.83%
72
Outperform
¥2.99B9.28
2.50%-0.34%-21.06%
71
Outperform
¥9.59B13.64
1.26%18.30%37.13%
71
Outperform
¥4.22B10.29
15.25%93.03%
66
Neutral
¥10.37B19.20
1.22%20.37%-5.97%
51
Neutral
$7.69B-0.19-46.01%2.25%22.94%-0.68%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:7133
HYUGA PRIMARY CARE Co.,Ltd.
1,295.00
-13.20
-1.01%
JP:2374
Saint-Care Holding Corp.
801.00
76.85
10.61%
JP:2425
Care Service Co., Ltd.
787.00
-51.50
-6.14%
JP:7061
Japan Hospice Holdings Inc.
1,230.00
-115.23
-8.57%
JP:7091
Living Platform Ltd.
942.00
-56.00
-5.61%
JP:7129
Miahelsa Holdings Corporation
1,145.00
-5.62
-0.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 14, 2025